Hilltop Holdings Inc SEC Filings

The Schedule 13G filed on 3 July 2025 reveals that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC collectively own 153,219 Bone Biologics Corporation (BBLG) common shares, equal to 9.99 % of the class. The position consists of 148,500 issued shares and 4,791 shares underlying Intracoastal Warrant 2; all voting and dispositive power is shared among the three reporting persons.

The stake originates from a Securities Purchase Agreement signed on 27 June 2025, under which the Company issued 60,000 shares and seven separate warrants to Intracoastal. Each warrant carries an ownership “blocker” that prevents exercise if the group’s beneficial ownership would exceed 9.99 % (or 4.99 % for several smaller warrants). Because of these blockers the group remains below the 10 % threshold required for Section 16 reporting.

Without the blocker provisions, the reporting group could control up to 821,294 shares immediately after the SPA and 719,794 shares as of 3 July 2025—more than 1.3× the 545,260 shares outstanding on 20 June 2025—indicating significant potential dilution for existing holders if the warrants become exercisable.

The certification section states the securities were not acquired to influence control of the issuer. Nonetheless, investors should monitor (1) the pace of warrant exercises, (2) any amendments to blocker thresholds, and (3) future Schedule 13D/G updates that could signal a change in intent or ownership.

The Schedule 13G filed on 3 July 2025 reveals that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC collectively own 153,219 Bone Biologics Corporation (BBLG) common shares, equal to 9.99 % of the class. The position consists of 148,500 issued shares and 4,791 shares underlying Intracoastal Warrant 2; all voting and dispositive power is shared among the three reporting persons.

The stake originates from a Securities Purchase Agreement signed on 27 June 2025, under which the Company issued 60,000 shares and seven separate warrants to Intracoastal. Each warrant carries an ownership “blocker” that prevents exercise if the group’s beneficial ownership would exceed 9.99 % (or 4.99 % for several smaller warrants). Because of these blockers the group remains below the 10 % threshold required for Section 16 reporting.

Without the blocker provisions, the reporting group could control up to 821,294 shares immediately after the SPA and 719,794 shares as of 3 July 2025—more than 1.3× the 545,260 shares outstanding on 20 June 2025—indicating significant potential dilution for existing holders if the warrants become exercisable.

The certification section states the securities were not acquired to influence control of the issuer. Nonetheless, investors should monitor (1) the pace of warrant exercises, (2) any amendments to blocker thresholds, and (3) future Schedule 13D/G updates that could signal a change in intent or ownership.

The Schedule 13G filed on 3 July 2025 reveals that Mitchell P. Kopin, Daniel B. Asher and Intracoastal Capital LLC collectively own 153,219 Bone Biologics Corporation (BBLG) common shares, equal to 9.99 % of the class. The position consists of 148,500 issued shares and 4,791 shares underlying Intracoastal Warrant 2; all voting and dispositive power is shared among the three reporting persons.

The stake originates from a Securities Purchase Agreement signed on 27 June 2025, under which the Company issued 60,000 shares and seven separate warrants to Intracoastal. Each warrant carries an ownership “blocker” that prevents exercise if the group’s beneficial ownership would exceed 9.99 % (or 4.99 % for several smaller warrants). Because of these blockers the group remains below the 10 % threshold required for Section 16 reporting.

Without the blocker provisions, the reporting group could control up to 821,294 shares immediately after the SPA and 719,794 shares as of 3 July 2025—more than 1.3× the 545,260 shares outstanding on 20 June 2025—indicating significant potential dilution for existing holders if the warrants become exercisable.

The certification section states the securities were not acquired to influence control of the issuer. Nonetheless, investors should monitor (1) the pace of warrant exercises, (2) any amendments to blocker thresholds, and (3) future Schedule 13D/G updates that could signal a change in intent or ownership.

Form 4 Overview: Hilltop Holdings Inc. (HTH) filed a Form 4 covering Director/Officer Charlotte Jones Anderson. The filing reports a single transaction dated 06/30/2025.

Transaction Details: Anderson acquired 50 shares of HTH common stock under the company’s 2020 Equity Incentive Plan, which compensates outside directors each quarter. The grant is recorded at an average price of $29.852 per share, a valuation methodology based on the 06/16/25–06/30/25 closing-price average. Post-transaction, Anderson’s direct beneficial ownership stands at 16,228 shares.

Context & Materiality: The market value of the shares acquired is roughly $1.5 thousand, representing a de minimis addition relative to both Anderson’s existing stake and Hilltop’s market capitalization. No derivatives were involved, and there were no dispositions. Because the trade was compensation-related and routine in size, it is unlikely to influence near-term trading sentiment or valuation models.

Takeaway for Investors: Routine equity compensation grants can signal continued alignment between directors and shareholders, but the size of this award is too small to be considered a meaningful indicator of insider conviction. The filing is therefore viewed as informational rather than market-moving.

Hilltop Holdings Inc. (HTH) Form 4 filing: Director and Hilltop Securities Chairman Jonathan S. Sobel reported the acquisition of 221 shares of Hilltop Holdings common stock on 30 June 2025.

• Transaction type: “A” (acquired). The shares were issued under the company’s 2020 Equity Incentive Plan as quarterly board compensation, not an open-market purchase.
• Average price: $29.852 per share, calculated from the 15-day closing-price average ending 30 June 2025 (footnote 2).
• Post-transaction ownership: Sobel now directly holds 26,471.694 shares.
• Insider role: Director and Officer (Hilltop Securities Chairman).

No derivative securities were reported. The filing represents routine equity compensation, adding less than 1% to Sobel’s total position and is unlikely to be financially material to Hilltop Holdings’ outstanding share count.

Hilltop Holdings Inc. (HTH) Form 4 filing: Director and Hilltop Securities Chairman Jonathan S. Sobel reported the acquisition of 221 shares of Hilltop Holdings common stock on 30 June 2025.

• Transaction type: “A” (acquired). The shares were issued under the company’s 2020 Equity Incentive Plan as quarterly board compensation, not an open-market purchase.
• Average price: $29.852 per share, calculated from the 15-day closing-price average ending 30 June 2025 (footnote 2).
• Post-transaction ownership: Sobel now directly holds 26,471.694 shares.
• Insider role: Director and Officer (Hilltop Securities Chairman).

No derivative securities were reported. The filing represents routine equity compensation, adding less than 1% to Sobel’s total position and is unlikely to be financially material to Hilltop Holdings’ outstanding share count.

Hilltop Holdings Inc. (HTH) Form 4 filing: Director and Hilltop Securities Chairman Jonathan S. Sobel reported the acquisition of 221 shares of Hilltop Holdings common stock on 30 June 2025.

• Transaction type: “A” (acquired). The shares were issued under the company’s 2020 Equity Incentive Plan as quarterly board compensation, not an open-market purchase.
• Average price: $29.852 per share, calculated from the 15-day closing-price average ending 30 June 2025 (footnote 2).
• Post-transaction ownership: Sobel now directly holds 26,471.694 shares.
• Insider role: Director and Officer (Hilltop Securities Chairman).

No derivative securities were reported. The filing represents routine equity compensation, adding less than 1% to Sobel’s total position and is unlikely to be financially material to Hilltop Holdings’ outstanding share count.

General Mills (GIS) Form 4 filing dated 07/02/2025 discloses routine equity transactions by Group President Jonathan Nudi. On 06/30/2025 Nudi’s spouse indirectly acquired 1,086 common shares at a stated price of $0.00, increasing the family’s indirect holding to 17,700.164 shares. Direct ownership remains at 137,716.139 shares, while a trust holds 1,833.98 shares.

The filing also records the award of a non-qualified stock option for 5,429 shares at an exercise price of $51.81. The option vests in four equal annual installments beginning 30 Jun 2026 and expires 30 Jul 2035. All derivative positions are reported as indirectly held by the spouse.

No sale transactions, price-paid cash outflows, or changes to executive roles were reported. The activity represents standard executive compensation and a modest share acquisition that is immaterial relative to General Mills’ share count.

Micron Technology (MU) has filed a Form 4 reporting routine board compensation for Director Robert Holmes Swan. On 30 June 2025 the director received 250 Restricted Stock Units (RSUs) at an exercise price of $0.00 in lieu of a cash retainer. The award vested 100 % on the grant date. Because Mr. Swan elected to defer settlement, the underlying shares will be issued to him within 15 days of his separation from the board. The filing also lists 4,444 common shares held directly after the reported transactions; no open-market purchases or sales were disclosed.

• The RSU grant is a non-cash, non-dilutive compensation expense for Micron.
• No change in corporate cash position or insider buying/selling signal.
• Filing maintains compliance with Section 16 reporting requirements.

The event does not materially impact Micron’s financials or governance profile and is viewed as neutral for shareholders.